This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hopewell, J W Articles by Chakrabarti, K Search for Related Content PubMed PubMed Citation Articles by Hopewell, J W Articles by Chakrabarti, K Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOXORUBICIN Social Bookmarking                         What's this?

Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent

Normal Tissue Radiobiology Group, Research Institute (University of Oxford), The Churchill Hospital, Oxford, OX3 7LJ, UK

R Duncan

Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, Wales, UK

D Wilding

K Chakrabarti

Normal Tissue Radiobiology Group, Research Institute (University of Oxford), The Churchill Hospital, Oxford, OX3 7LJ, UK

PK2 is a polymeric anticancer conjugate composed of an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone and pendant doxorubicin (DOX) linked via a Gly-Phe-Leu-Gly peptide spacer. Additionally galactose residues are present to facilitate liver targeting. To justify clinical evaluation of PK2 it was necessary to determine its late cardiotoxicity compared to that of free DOX. A well standardised Sprague–Dawley rat model was used with either intravenous (IV) administration (4, 8 and 12 mg/kg DOX equivalent) or intraperitoneal (IP) administration (12, 18, 24 and 36 mg/kg DOX equivalent) of PK2. This variation in the route was due to the limited solubility of PK2 at higher doses. PK2 showed two to three times less acute toxicity (assessed by the maximum reduction in body weight in the first 2 weeks) than free DOX, and both compounds were less toxic when given IP. No animals given PK2 IV showed clinical signs of cardiotoxicity, the only toxicity seen was abnormal tooth growth (50% of the animals receiving 12 mg/kg, DOX equivalent). In contrast, several animals receiving free DOX (1–4 mg/kg) IV died due to cardiotoxicity in an approximately dose-related manner. All animals receiving free DOX (4 mg/kg) died by 12 weeks. Following IPadministration of PK2 there were only two late deaths related to cardiotoxicity and these were in the 24 mg/kg DOX equivalent group. All animals receiving PK2 at the highest dose (36 mg/kg DOX equivalent) died within 4 weeks, cardiotoxicity was not the main contributing factor. In this study, PK2 displayed a 5-fold reduction in cardiotoxicity relative to free DOX and this supported the progression of PK2 into early clinical investigation.

Key Words: PK2 • cardiotoxicity • HPMA copolymers • polymer therapeutics

Human & Experimental Toxicology, Vol. 20, No. 9, 461-470 (2001)
DOI: 10.1191/096032701682693017


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				T K Yeung, K Chakrabarti, D Wilding, and J W Hopewell Modification of doxorubicin-induced cardiotoxicity: manipulation of the dosage schedule Human and Experimental Toxicology, November 1, 2002; 21(11): 607 - 614. [Abstract] [PDF]